PF 04457845

Drug Profile

PF 04457845

Alternative Names: PF-04457845; PF-4457845

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Developer Linkoping University; Pfizer; SpringWorks Therapeutics; Stockholm Centre for Dependency Disorders
  • Class Benzylidene compounds; Piperidines; Pyridazines; Small molecules
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Psychiatric disorders
  • Discontinued Alcoholism; Pain; Post-traumatic stress disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 29 Dec 2017 Yale University plans the FAAH-I MULTI phase II trial for Substance-related-disorders in March 2018 , (NCT03386487)
  • 25 Sep 2017 SpringWorks Therapeutics, a Pfizer spinoff is developing PF 04457845
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top